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The preponderance of evidence
supports an aryl hydrocarbon
receptor-dependent mechanism of
action of tapinarof
To the Editor: We thank Haarmann-Stemmann et al1
for their interest in our article on the mechanism
of action of tapinarof, a novel, first-class,
small-molecule topical therapeutic aryl hydrocarbon
receptor (AhR)-modulating agent in development
for the treatment of psoriasis and atopic dermatitis.
While we attribute a major part of tapinarof’s
clinical effect in psoriasis to its specific binding and
activation of AhR, we did not intend to rule out the
possibility of additional beneficial effects unexplained by AhR signaling. In fact, in our original
article, we note that tapinarof, as a stilbene molecule,
has intrinsic antioxidant and reactive oxygen
species-scavenging activities, thus also acts in an
AhR-independent manner. We also concur with
Haarmann-Stemmann et al1 that cell-specific and
other factors are likely to play important roles in the
clinical effect of tapinarof.
However, we assert that the preponderance of
good quality evidence supports an AhR-dependent
mechanism of action of tapinarof, explaining a major
part of its highly significant efficacy recently reported
in 2 large phase 3 trials.2 In particular, evidence that
knocking out AhR expression in mouse models
abrogates the beneficial effects of tapinarof on
psoriasiform inflammation strongly supports an
AhR-dependent mechanism.3
Although absence of evidence does not equate
to evidence of absence, to the best of our knowledge the authors’ assertion that tapinarof clears
psoriasis by altering the skin microbiome is not
supported by the same level of rigorous empirical
evidence. These additional pathways may explain
the modest efficacy of unstandardized applications
such as coal tar, making it tempting to speculate
that these pathways may also be involved with
tapinarof. However, evidence on their contribution
to the clinical efficacy of the active principle in
tapinarof cream 1%, which is a well-characterized,
naturally identified, small-molecule pharmacologic
product, is insufficient.
Moreover, in a maximal-use pharmacokinetic
study, using tapinarof cream 1% once daily was
shown to result in negligible systemic exposure,
even under conditions that maximize the potential for drug absorption.4 Thus, while we cannot
rule out that the active principle may have
beneficial skin microbiome effects, negligible
systemic exposure with topical tapinarof cream
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1% is unlikely to have significant effects outside
of the skin.4
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